Glass Wall Systems IPO Review: 86% OFS, 19x

Key takeaways

• The book is ₹427.89 crore: ₹60 crore fresh for a glass-processing unit, ₹367.89 crore OFS — 86% of the issue.
• India Business Excellence Fund IIA is selling ₹271.96 crore. Promoters Jawahar and Eshan Hemrajani sell ₹46.05 crore and ₹49.88 crore.
• FY26 revenue from operations was ₹456.97 crore and PAT ₹83.79 crore, after an FY25 revenue dip. Operating cash was positive all three years (₹42.7 / ₹73.0 / ₹73.3 crore).
• At ₹182, post-issue mcap is ₹1,600.42 crore, or 19.1x FY26 — versus Innovators Façade Systems at 15.9x (4 Sep 2026).
• Day 1 (8 Sep, 10:12 IST) printed 0.15x. An unofficial GMP of ₹35 has been quoted — unofficial, unregulated, often wrong.

The deal in one paragraph

Glass Wall Systems designs and installs façades in India and ships product to the US and Australia. The books are clean in one important way: three years of operating cash, almost no debt, and a 64% FY26 revenue recovery. The offer is not a growth raise. ₹60 crore comes in; ₹368 crore goes out, most of it a PE exit. Nineteen times last year’s earnings is a premium to the only listed façade peer, on a year that followed a dip. My read is the checklist at the end.

Data

Issue structure

Item	Figure	Units
Total issue	427.89	₹ cr
Fresh issue	60.00	₹ cr
OFS	367.89	₹ cr
of which IBE Fund IIA	271.96	₹ cr
Price band	172–182	₹ / share
Lot	82	shares (₹14,924 at the cap)
Promoter group	64.11 → 55.72	%
Anchor (7 Sep)	128.37	₹ cr
Listing (tentative)	16 Sep 2026	NSE + BSE

Source: Chittorgarh; Groww. Fresh proceeds: Vile Bhagad glass-processing unit.

Financials (restated consolidated, ₹ cr)

	FY24	FY25	FY26
Revenue from operations	304.34	278.33	456.97
EBITDA	54.70	73.01	105.20
EBITDA margin (on ops)	18.0%	26.2%	23.0%
PAT	20.25	57.51	83.79
Operating cash flow	42.72	72.95	73.25
Net worth	122.60	175.75	261.58
Borrowings	24.85	8.46	6.68
EPS (₹)	1.81	6.21	9.90

Units: ₹ crore except EPS and margins. Source: SEBI abridged prospectus. FY24 PAT includes a ₹16.19 crore exceptional item (IPO Watch). Order book prints disagree — ₹981.55 crore (IPO Watch) vs ₹846 crore (broker note) — so I do not use either in the title.

Valuation at the upper band

Metric	At ₹182
Post-issue mcap	₹1,600.42 cr
P/E post-issue FY26	19.1x
P/E on FY25 PAT	27.8x
P/B on NAV ₹30.91	5.89x
Innovators Façade P/E (4 Sep 2026)	15.9x
Innovators FY26 PAT	₹13.56 cr

Units: rupees crore and times. Source: Chittorgarh; IPO Watch; Trade Brains. One peer, smaller and less profitable — useful as a floor, not a clone.

Subscription and unofficial GMP

Day 1, 8 Sep 2026, 10:12 IST (Groww): overall 0.15x, retail 0.22x, NII 0.18x, QIB 0.00x. Anchors already put in ₹128.37 crore on 7 Sep. Livemint quoted an unofficial GMP of +₹35 versus ₹182. Grey-market prints are informal and often wrong.

Risks

• 86% OFS, including a ₹272 crore PE sale.
• One thin peer at 16x; 19x is a premium on a recovery year.
• FY25 revenue decline; FY26 needs another year to look like a run-rate.
• Customer / supplier concentration and overseas jobs (Trade Brains).
• Contingent liabilities ₹33.41 crore as of 31 Mar 2026 (IPO Watch).
• Façade EPC is tied to the real-estate cycle.

What to watch

Five checks. At ₹182 this issue clears 2 of 5 (business, numbers). Price is partial. The OFS is the red flag that does not clear.

What would change my mind: two post-listing quarters of revenue at or above ₹110 crore with operating cash still positive — or a live print near the peer multiple on FY26. Allotment 11 Sep; listing tentatively 16 Sep 2026.

A companion video is planned; it will quote only numbers that appear here or in docs/ipo_analysis/glass_wall_systems.md.

Sources

1. SEBI abridged prospectus — restated financials and KPIs — accessed 8 Sep 2026.
2. Chittorgarh — issue, OFS sellers, objects, share counts — accessed 8 Sep 2026.
3. Groww — Day-1 subscription — accessed 8 Sep 2026.
4. IPO Watch — P/E, exceptional item, contingent liability — accessed 8 Sep 2026.
5. Trade Brains — Innovators Façade comparison — accessed 8 Sep 2026.
6. Livemint — unofficial GMP — accessed 8 Sep 2026.

Disclaimer

AlphaResearch is not a SEBI-registered investment adviser or research analyst. This article is educational analysis based on publicly available information and is not investment advice or a recommendation to buy, sell, hold, subscribe to or avoid any security. Figures are taken from the sources listed above and may contain errors; verify them in the original filings. Investing in securities involves risk, including loss of principal. Consult a SEBI-registered adviser before making investment decisions.

Position disclosure: none.